Dexametasone
ApprovedSmall molecule
Dexametasone is one of 31 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.
1
Indications
4
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Iclusig
TakedaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cellcept
RochePhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
Perioperative Pain1 trial
Recurrent Laryngeal Nerve1 trial
Post Operative Pain1 trial
The Effect of Dexamethasone in Full Pulpotomy on Postoperative Pain in Permanent Molars
Completed·—·N/A·NCT07233577·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexametasone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Malaya